VU 0155069

Potent and selective PLD1 inhibitor CAS# 1130067-06-9

VU 0155069

Catalog No. BCC7715----Order now to get a substantial discount!

Product Name & Size Price Stock
VU 0155069: 5mg $127 In Stock
VU 0155069: 10mg Please Inquire In Stock
VU 0155069: 20mg Please Inquire Please Inquire
VU 0155069: 50mg Please Inquire Please Inquire
VU 0155069: 100mg Please Inquire Please Inquire
VU 0155069: 200mg Please Inquire Please Inquire
VU 0155069: 500mg Please Inquire Please Inquire
VU 0155069: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of VU 0155069

Number of papers citing our products

Chemical structure

VU 0155069

3D structure

Chemical Properties of VU 0155069

Cas No. 1130067-06-9 SDF Download SDF
PubChem ID 56972237 Appearance Powder
Formula C26H28Cl2N4O2 M.Wt 499.43
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 50 mM in ethanol
Chemical Name N-[(2S)-1-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]naphthalene-2-carboxamide;hydrochloride
SMILES CC(CN1CCC(CC1)N2C3=C(C=C(C=C3)Cl)NC2=O)NC(=O)C4=CC5=CC=CC=C5C=C4.Cl
Standard InChIKey RQULTQQAHGYYDG-LMOVPXPDSA-N
Standard InChI InChI=1S/C26H27ClN4O2.ClH/c1-17(28-25(32)20-7-6-18-4-2-3-5-19(18)14-20)16-30-12-10-22(11-13-30)31-24-9-8-21(27)15-23(24)29-26(31)33;/h2-9,14-15,17,22H,10-13,16H2,1H3,(H,28,32)(H,29,33);1H/t17-;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of VU 0155069

DescriptionPotent and selective phospholipase D1 (PLD1) inhibitor (IC50 values are 46 and 933 nM for PLD1 and PLD2 respectively). Inhibits migration of human and mouse breast cancer cell lines in transwell assays.

VU 0155069 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VU 0155069 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of VU 0155069

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0023 mL 10.0114 mL 20.0228 mL 40.0457 mL 50.0571 mL
5 mM 0.4005 mL 2.0023 mL 4.0046 mL 8.0091 mL 10.0114 mL
10 mM 0.2002 mL 1.0011 mL 2.0023 mL 4.0046 mL 5.0057 mL
50 mM 0.04 mL 0.2002 mL 0.4005 mL 0.8009 mL 1.0011 mL
100 mM 0.02 mL 0.1001 mL 0.2002 mL 0.4005 mL 0.5006 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on VU 0155069

[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]

Ned Tijdschr Geneeskd. 2017;161:D861.

On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.[Pubmed:19268584]

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1916-20.

This Letter describes the synthesis and structure-activity-relationships (SAR) of isoform-selective PLD inhibitors. By virtue of the installation of alternative halogenated piperidinyl benzimidazolone privileged structures, in combination with a key (S)-methyl group, novel PLD inhibitors with low nM potency and unprecedented levels of PLD1 isoform selectivity (approximately 1700-fold) over PLD2 were developed.

Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.[Pubmed:19136975]

Nat Chem Biol. 2009 Feb;5(2):108-17.

Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid. Phosphatidic acid participates in both G protein-coupled receptor and receptor tyrosine kinase signal transduction networks. The lack of potent and isoform-selective inhibitors has limited progress in defining the cellular roles of PLD. We used a diversity-oriented synthetic approach and developed a library of PLD inhibitors with considerable pharmacological characterization. Here we report the rigorous evaluation of that library, which contains highly potent inhibitors, including the first isoform-selective PLD inhibitors. Specific members of this series inhibit isoforms with >100-fold selectivity both in vitro and in cells. A subset of inhibitors was shown to block invasiveness in metastatic breast cancer models. These findings demonstrate the power of diversity-oriented synthesis combined with biochemical assays and mass spectrometric lipid profiling of cellular responses to develop the first isoform-selective PLD inhibitors--a new class of antimetastatic agents.

Description

VU0155069 (CAY10593), compound 69, is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays.

Keywords:

VU 0155069,1130067-06-9,Natural Products,Phospholipase, buy VU 0155069 , VU 0155069 supplier , purchase VU 0155069 , VU 0155069 cost , VU 0155069 manufacturer , order VU 0155069 , high purity VU 0155069

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: